TUDCA has moderate evidence for cholestatic (bile-flow) conditions, but its benefit for the hepatocellular injury seen with fenbendazole is extrapolated rather than directly proven
India Asian J Adv Basic Sci 7(2):4249 Kumar G, Rana S (2016) Eco-ethnological and aromatic plants of Jahu valley region Himachal Pradesh, India
We can talk by email, skype, whatsapp, phone or whatever you feel convenient
Protocol 1: moderate weight loss (10-15% body weight) Goal: Steady, sustainable weight loss with minimal side effects Tirzepatide approach: Standard escalation to 5-7.5 mg Hold at the dose where you achieve consistent weekly loss of 0.5-1% body weight Expected timeline: 24-36 weeks to target Likely maintenance dose: 5-7.5 mg Retatrutide approach: Standard escalation to 4 mg 4 mg delivered 12.9% weight loss at 24 weeks in trials Hold at 4 mg if achieving target rate Expected timeline: 20-30 weeks to target For moderate goals, both compounds work well at their lower dose ranges
Taken together, these data reinforce the emerging paradigm of a multimodal and personalized therapeutic approach, which will likely form the foundation of future obesity management
